Vienna, Austria, January 27th: EUCODIS Bioscience is glad to announce that it has teamed up with Tube Pharmaceuticals to bring the production of tubulysins to a commercial level. Tube Pharmaceuticals and EUCODIS now jointly produce and commercialize tubulysin A and B and other variants of this cytotoxic compound.
Tubulysins are isolated from the culture broth of strains of Archangium gephyra and Angiococcus disciformis, both members of a Gram negative, soil-dwelling group of bacteria known as myxobacteria. The production process has been up-scaled and tubulysin A and B are now produced by EUCODIS Bioscience.
Novel Enzymatic, 1-Step Site-Specific Protein Conjugation Technology for ADC Production
Berlin, Germany, and Vienna, Austria, April 19th: ProBioGen AG, a leading specialist for contract development and manufacturing of complex glycoproteins and EUCODIS Bioscience, an expert in enzyme engineering, today jointly announced the signature of an exclusive license agreement on C-LiNK (CTAT), an innovative, site-specific ADC conjugation technology. Under the agreement ProBioGen gains exclusive rights to commercialize EUCODIS’ enzymatic C-terminal linking technology, and to offer it, together with its antibody development services, royalty-free to ADC-developing parties.
CTATTM is an innovative enzymatic linker technology for conjugating different payloads with antibodies, without affecting their specificity, binding properties or stability. In the presented xenograft trial, the tested CTAT-ADC showed superior efficacy versus a commercially available ADC.